Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin.
In this study, we assessed the efficacy and safe usage of the oral contraceptive, Diane-35, in the treatment of polycystic ovary syndrome (PCOS) when combined with the drug metformin. Eighty-two patients with PCOS were randomly divided into two equal groups: Diane-35 treatment group and Diane-35 plus metformin group. Three treatment cycles were administered. Patients' biomedical data such as height, weight, waist circumference, hip circumference, body fat percentage, acne score, hirsutism score and serum hormone levels were selected, which were tested between the second and the fifth day of the menstrual cycle and follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), blood glucose, blood lipids and insulin levels(IR) were analyzed. Significant reduction in body mass index (BMI), acne score, LH and T levels were observed in both groups after three months of treatment; on the other hand, high-density lipoprotein cholesterol (HDL) concentration elevated (p < 0.05). Combined treatment group had a significant change in BMI index and fasting blood glucose levels compared to Diane-35 alone treatment group (p < 0.05). With personalized nutrition and exercise program, Diane-35 only group or Diane-35 plus metformin group had both significantly lowered their serum testosterone levels and had improved acne symptoms. Diane-35 plus metformin combination had shown reduced fat percentage levels in patients with PCOS, and had shown improved glucose and lipid metabolism.
a Department of Gynecology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , P.R. China.
Wei
W
Feng
a Department of Gynecology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , P.R. China.
Yan-Yan
YY
Jia
a Department of Gynecology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , P.R. China.
Dong-Ya
DY
Zhang
a Department of Gynecology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , P.R. China.
Hui-Rong
HR
Shi
D000328:Adult; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D017373:Cyproterone Acetate / Q000008:administration & dosage / Q000494:pharmacology*; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology*; D017063:Outcome Assessment, Health Care; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000188:drug therapy*; D055815:Young Adult
D000726:Androgen Antagonists; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D008687:Metformin
Body mass index; diane 35; hirsutism; metformin; polycystic ovary syndrome